BioFire
Forecast overview
- Subagency
- IHS
- NAICS
- 423450
- Program office
- 75H711
Purchase analyzer/lease analyzer; purchase test panels; Spotfire 2 or equivalent-FDA approved PCR CLIA waived analyzer that tests the following using one collection sample: adenoviruse, coronavirus (SARS-CoV-2), seasonal coronavirus, human metapneumovirus, human rhinovirus/enterovirus, influenza A, Influenza B, parainfluenza virus, influenza A/H3, Influenza A/H1-2009, respiratory syncytial virus, bordetella parapertussis, bordetella pertussis, chlamydia pneumonia, and mycoplasma pneumonia.
Related federal terms
- NAICS — North American Industry Classification System
Acquisition timeline
- Last verified on RFPCapture
- 2026-08-31
- Estimated solicitation
- 10/2024 (agency estimate)
- Estimated award
- 11/2025 (agency estimate)
- Expected period of performance end
- 11/2025 (agency estimate)
Why watch this
- This forecast is tied to an agency with active procurement in this NAICS.
- Recent awards exist in this market.
- Recompete context: Related award history found; treat as related public awards unless SAM.gov confirms a recompete.
Market context
- NAICS market
- NAICS 423450
- Recent comparable awards
- 8 from public USAspending records
- Reported awardee
- GLAXOSMITHKLINE, LLC
- Agency spending trend
- $238.6M · Declining
Action links
Track this forecast in CaptureIQ
Source
- Source
- HHS SBCX Forecast Export
- Source file
- Forecast.csv
- Official source
- Agency forecast source
- Last verified
- 2026-08-31